DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 199 filers reported holding DENALI THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,652 | -30.1% | 467,851 | +0.0% | 0.02% | -20.0% |
| Q2 2023 | $13,805 | +46.8% | 467,800 | +14.6% | 0.02% | +66.7% |
| Q1 2023 | $9,403 | +35.5% | 408,100 | +63.5% | 0.01% | +33.3% |
| Q4 2022 | $6,941 | -99.9% | 249,600 | -36.4% | 0.01% | -47.1% |
| Q3 2022 | $12,037,000 | +61.3% | 392,200 | +54.7% | 0.02% | +88.9% |
| Q2 2022 | $7,461,000 | +89.2% | 253,500 | +106.8% | 0.01% | +80.0% |
| Q1 2022 | $3,944,000 | +62.8% | 122,600 | +125.8% | 0.01% | +66.7% |
| Q4 2021 | $2,422,000 | -49.8% | 54,300 | -43.2% | 0.00% | -50.0% |
| Q3 2021 | $4,823,000 | +434.7% | 95,600 | +731.3% | 0.01% | +500.0% |
| Q2 2021 | $902,000 | -94.1% | 11,500 | -95.7% | 0.00% | -94.7% |
| Q1 2021 | $15,183,000 | +722.9% | 265,900 | +416.3% | 0.02% | +850.0% |
| Q3 2020 | $1,845,000 | +41.1% | 51,500 | -18.3% | 0.00% | +100.0% |
| Q2 2019 | $1,308,000 | – | 63,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $219,569,000 | 28.65% |
| ARCH Venture Management, LLC | 5,168,749 | $152,116,000 | 18.54% |
| Casdin Capital, LLC | 1,500,000 | $44,145,000 | 3.73% |
| Flagship Pioneering Inc. | 2,619,968 | $77,106,000 | 2.90% |
| Yiheng Capital Management, L.P. | 1,014,684 | $29,862,000 | 1.71% |
| SECTORAL ASSET MANAGEMENT INC | 202,100 | $5,948,000 | 1.20% |
| GILDER GAGNON HOWE & CO LLC | 1,956,820 | $57,589,000 | 1.03% |
| Artal Group S.A. | 600,000 | $17,658,000 | 0.94% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $158,024,002 | 0.87% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $283,000 | 0.69% |